Muhammad Junaid Niaz

Author

Also Known As

M Junaid Niaz, M. J. Niaz, M. Junaid Niaz, M.J. Niaz, Maria Niaz, Mu-hammad Junaid Niaz, Muhammad J Niaz, Muhammad J. Niaz, Muhammad Ju-naid Niaz, Muhammad Junaid Niaz

Publications

498

Citations

H-Index

Concepts

All Affiliations

Cornell University Weill Cornell Medicine Molecular Innovations (United States)

About

Muhammad Junaid Niaz is an author at Cornell University specializing in radiation oncology, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	120
2	Immunology	2	2	40
3	Pharmacology	2	2	54
4	Health Sciences	1	1	24
5	Radiation Medicine	1	1	10

Muhammad Junaid Niaz

Publications

264

Citations

H-Index

Page 1

	Year	Citations
Phase I trial of docetaxel plus lutetium-177-labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 (177Lu‐J591) for metastatic castration‐resistant prostate cancer Jaspreet S. Batra, Muhammad Junaid Niaz, Young E. Whang, Urologic Oncology Seminars and Original Investigations UrologyGenitourinary CancerMedicineCancer TreatmentProstatic Disease	2020	45
Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer Panagiotis J. Vlachostergios, Muhammad Junaid Niaz, Michael Sun, Frontiers in Oncology	2021	41
Pilot Study of Hyperfractionated Dosing of Lutetium-177–Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (177Lu-J591) for Metastatic Castration-Resistant Prostate Cancer Muhammad Junaid Niaz, Jaspreet S. Batra, Ryan D. Walsh, The Oncologist	2020	36
Phase I study of <sup>225</sup>Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC). Scott T. Tagawa, Michael Sun, Oliver Sartor, Journal of Clinical Oncology Psma UptakeImmunologyPharmacotherapyMetronomic ChemotherapyImmunotherapy	2021	30
Imaging expression of prostate‐specific membrane antigen and response to PSMA‐targeted β‐emitting radionuclide therapies in metastatic castration‐resistant prostate cancer Panagiotis J. Vlachostergios, Muhammad Junaid Niaz, Myrto Skafida, The Prostate	2021	25
Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC). Scott T. Tagawa, Joseph R. Osborne, Muhammad Junaid Niaz, Journal of Clinical Oncology PharmacotherapySmall Molecule LigandsPre-clinical PharmacologyOncologyGenitourinary Cancer	2020	24
Functional Outcome After Decompressive Craniectomy in Patients with Dominant or Non-Dominant Malignant Middle Cerebral Infarcts Bilal Alam, Ahmed Bukhari, Salman Assad, Cureus	2017	16
Pilot study of the diagnostic utility of <sup>89</sup>Zr‐df‐IAB2M and <sup>68</sup>Ga‐PSMA‐11 PET imaging and multiparametric MRI in localized prostate cancer Panagiotis J. Vlachostergios, Muhammad Junaid Niaz, Charlene Thomas, The Prostate	2022	15
Preliminary results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC) Scott T. Tagawa, Joseph R. Osborne, Amy Hackett, Annals of Oncology Surgical OncologyUrologyDose 177Lu-psma-617Genitourinary CancerMedicine	2019	11
Dermatofibrosarcoma Protuberans: The Current State of Multidisciplinary Management. Marigdalia K. Ramirez‐Fort, Barbara Meier, Muhammad Junaid Niaz, PubMed	2020	11

Page 1